Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

PVP-guidet dekongestiv terapi i HF 2 (PERIPHERAL-HF2)

29. september 2026 opdateret af: Başakşehir Çam & Sakura City Hospital

Perifer venetrykstyret dekongestiv terapi ved hjertesvigt 2

The investigators hypothesize that a simple assessment of peripheral venous pressure (PVP) will better predict the diuretic need and long-term outcomes (all cause mortality, all cause rehospitalization, emergency department visits) compared to standard evaluation.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Intervention / Behandling

Detaljeret beskrivelse

I. BACKGROUND AND SIGNIFICANCE

Precise assessment of volume status is essential in diagnosis and management of diuretic therapy in patients hospitalized for heart failure (HF). Unfortunately, no clear guidelines are present for in-hospital management of congestion. Consequently, nearly half of the patients hospitalized for congestive HF are discharged with persistent congestion. This contributes to high rates of readmission and mortality.

Recently, it has been shown that a simple assessment of peripheral venous pressure (PVP) demonstrates a high correlation with central venous pressure (CVP), indicating that PVP may be useful in the standard bedside clinical assessment of volume status in HF patients to help guiding decongestive therapy.

II. THE HYPOTHESIS

The main hypothesis is as follows: A simple assessment of peripheral venous pressure (PVP) will better guide the diuretic need and long-term outcomes (all-cause mortality, all cause re-hospitalization, emergency department visits) compared to standard evaluation.

III. METHODS

  1. Application for Institutional Review Board (IRB)/Ethics board approval The study will be at participating centers. An IRB/Ethics board approval has been obtained from Marmara University, Pendik Training and Research Hospital local ethics board.
  2. Study population Patients 18-99 years old who were admitted with a de novo or decompensated chronic HF and accept to participate in the study will be enrolled. Patients will be included regardless of ejection fraction or etiology of HF, but these will be noted as baseline variables. All patients or legal surrogate decision makers will be requested to provide a written informed consent prior to enrollment. Patients who withdraw their consent, those with upper extremity venous pathology, those with a baseline creatinine level equal to or above 3.5 mg/dL, those with severe stenotic valvular disease and hypertrophic cardiomyopathy will be excluded.
  3. Data Collection The study will start at participating centers on July 1, 2024.

Baseline variables Baseline variables will be entered to the electronic study form (RedCap).

Procedures A peripheral intravenous (IV) access, using an 18 to 22-gauge IV line, will be placed preferably to an upper extremity vein before enrollment. This line will be used to draw blood samples first. After blood samples were collected the subjects will be randomized to standard or PVP guided therapy groups. Randomization will be done using a computer-generated random allocation list via RedCap randomization module. The details of demographic characteristics, symptoms, physical examination findings and drug list will be noted to a standard electronic study form (see appendix). A routine electrocardiogram and echocardiogram will be performed at the earliest convenience.

After the blood samples were collected, line will be flushed carefully. PVP will be obtained by transducing a peripheral intravenous line after zeroing at the phlebostatic axis. The phlebostatic axis will be accepted as the midpoint between the anterior and posterior surfaces of the chest at the level of the fourth intercostal space meets with sternum, which is assumed to be correlated with the mid-level of the right atrium. The patient's arm will be placed parallel to the patient such that the position of the peripheral IV to be at the phlebostatic axis. Continuity of the peripheral IV line with the central venous system will be confirmed by demonstrating augmentation of the venous pressure waveform using manual or tourniquet circumferential occlusion of the extremity proximal to the catheter and modified Valsalva maneuver. If the pressure waveform failed to augment appropriately, data will not be collected, and the patient will be documented for study purposes as a technique failure. Daily fluid intake and output, weight, and biochemistry measurements, as required, will be done.

The patients in whom the first and the predischarge PVP cannot be measured due to technical issues (unable to provide upper extremity IV access, unable to confirm augmentation or Valsalva test) will be excluded from the study. Also, the patients requiring in-hospital intubation, high-dose inotrope or vasopressor infusion (≥10 mcg.kg-1.min-1 dopamine, dobutamine or equivalent), intraaortic balloon support, dialysis or veno-venous ultrafiltration will be excluded from the study (but these patients will be included in the in-hospital analyses).

In hospital diuretic treatment will be guided by ESC guidelines (see references). In the standard therapy arm, the treatment and the decision of discharge will be left to physicians' discretion. In the PVP-guided arm, a PVP < 9 mmHg will be targeted before discharge.

Outcomes The primary outcome of the study is the composite endpoint of all-cause mortality, all-cause hospitalization and all-cause emergency department visits. The secondary outcomes will include cardiovascular mortality, HF-related hospitalization, HF-related emergency department visits. This information on these outcomes will be obtained from the national electronic database. The follow-up duration is planned to be limited to one year.

Predefined secondary analyses

There will be subanalyses from the same cohort, as defined below:

  • The correlation between predischarge PVP and long-term outcomes. A multivariable analysis will also be executed for predicting the primary end point.
  • The correlation between the change in PVP during hospital stay and long-term outcomes. A multivariable analysis will also be executed for predicting the primary end point.
  • The correlation between the change in PVP during hospital stay and worsening renal function, renal injury, need for dialysis or veno-venous ultrafiltration.
  • The comparison of the two arms in terms of worsening renal function, need for dialysis or veno-venous ultrafiltration.
  • The comparison of the two arms in terms of EVEREST congestion score.
  • The comparison of the two arms in terms of the days in hospital.
  • The comparison of the two arms in terms of the number of repeat hospitalizations.
  • Usual patterns of diuretic use

Estimated number of subjects to be submitted:

We estimated that the enrollment of 621 participants would provide the study with a statistical power of 95% to detect a relative risk reduction of 26% (hazard ratio [HR] = 0.74) for the composite primary outcome (PVP-guided group: 40%, standard approach: 50%), using a two-sided test at the 0.05 significance level. This calculation assumes a 10% censoring rate and a 1-year follow-up period. The weighted event rate (πe=45%) was used to estimate the required number of events. To account for potential loss to follow-up and ensure robust analysis, the sample size was increased to 650 participants, maintaining equal allocation between groups (1:1 randomization).

Statistical Analysis Baseline characteristics will be summarized using standard descriptive statistics. Comparisons of relevant parameters between groups will be performed by chi-square, Fisher's exact test, Mann-Whitney U and student t-test, as appropriate. Kaplan-Meier analysis will be performed to determine the cumulative long-term mortality and composite outcome rates in subgroups. The mortality across groups will be compared using log-rank test. A Cox-regression model will be used to perform a survival analysis according to pre-discharge peripheral venous pressure and composite outcome. Baseline characteristics with a P value of 0.05 or less in the univariate analysis will be included and a step-down procedure will be applied for selection of final covariates. Statistical analyses will be performed with SPSS (version 24.0; SPSS Inc., Chicago, IL) and MedCalc Software (version 18.2.1 [Evaluation version]; MedCalc Software, Ostend, Belgium).

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

650

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Ankara, Tyrkiet (Türkiye), 6010
        • Ankara Etlik City Hospital
      • Antalya, Tyrkiet (Türkiye), 07070
        • Akdeniz University
      • Antalya, Tyrkiet (Türkiye), 07040
        • Antalya Atatürk State Hospital
      • Edirne, Tyrkiet (Türkiye), 22030
        • Trakya University
      • Erzurum, Tyrkiet (Türkiye), 25040
        • Erzurum Atatürk University Hospital
      • Eskişehir, Tyrkiet (Türkiye), 26080
        • Eskişehir City Hospital
      • Istanbul, Tyrkiet (Türkiye), 34668
        • Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
      • Istanbul, Tyrkiet (Türkiye)
        • Bağcılar Training and Research Hospital
      • Istanbul, Tyrkiet (Türkiye), 34303
        • Mehmet Akif Ersoy Training and Research Hospital
      • Istanbul, Tyrkiet (Türkiye), 3440
        • Basaksehir Cam and Sakura City Hospital
      • Izmir, Tyrkiet (Türkiye), 35665
        • Bakırçay University, Faculty of Medicine
      • Kahramanmaraş, Tyrkiet (Türkiye), 46700
        • Pazarcık State Hospital
      • Kars, Tyrkiet (Türkiye), 36100
        • Kafkas University Health Research and Application Hospital
      • Kütahya, Tyrkiet (Türkiye), 43100
        • Kütahya Health Sciences University
      • Tokat Province, Tyrkiet (Türkiye), 60030
        • Tokat Gaziosmanpaşa University
      • Şırnak, Tyrkiet (Türkiye), 73300
        • İdil State Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 99 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion criteria

  • Hospitalization for heart failure (de novo or decompensated chronic heart failure) irrespective of left ventricular ejection fraction
  • Age 18-99
  • Accept to participate

Exclusion criteria

  • A prior history of upper extremity venous disease
  • Serum creatinine ≥ 3.5 mg/dL
  • Severe stenotic valvular disease
  • Hypertrophic obstructive cardiomyopathy
  • Withdrawal of consent
  • Indwelling central venous catheter,
  • Implanted left ventricular assist device
  • History of heart transplantation
  • Clinical diagnosis of cardiogenic shock
  • Any right-to-left shunt

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: PVP-Guided

Peripheral venous pressure guided diuretic therapy arm

Diuretic therapy will be tailored according to peripheral venous pressure targets or standard approach

Aktiv komparator: Control

Standard dıuretic therapy arm

Diuretic therapy will be tailored according to peripheral venous pressure targets or standard approach

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Primary end point: Major adverse events (Mortality and rehospitalization)
Tidsramme: One year

The difference in the combined rate of all-cause mortality, all-cause hospitalization and all-cause emergency department visits

One year

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Secondary combined end point:Major cardiac adverse events (Cardiac mortality and hospitalization)
Tidsramme: One year

The difference in the combined rate of cardiovascular mortality, HF-related hospitalization, HF-related emergency department visits.

One year

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
PVP (discharge and delta) and long term outcomes
Tidsramme: One year

The correlation between predischarge the absolute amount of pre-discharge peripheral venous pressure (PVP in mmHg) and the change in PVP (in mmHg) during hospital stay and the rate of adverse long-term primary outcomes. (The higher the absolute PVP, more adverse outcomes is hypothesized. The higher the change in PVP during hospital stay, less the rate of adverse events is hypothesized). A multivariable analysis will also be executed for predicting the primary end point.

One year
PVP (delta and cohort) and in-hospital renal outcomes
Tidsramme: One year

The correlation between the change in PVP during hospital stay (in mmHg) and the rate of worsening renal function, renal injury, need for dialysis or veno-venous ultrafiltration.

One year
Congestion
Tidsramme: One year

The comparison of the two arms in terms of EVEREST congestion score (EVEREST congestion score, range 0-18, the higher the score, the higher the congestion (worse outcome))

One year
Hospital stay
Tidsramme: One year

The comparison of the two arms in terms of hospital stay (in days). Longer hospital stay duration is deemed as worse outome.

One year

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. juli 2024

Primær færdiggørelse (Faktiske)

1. juli 2025

Studieafslutning (Anslået)

1. december 2026

Datoer for studieregistrering

Først indsendt

25. juni 2024

Først indsendt, der opfyldte QC-kriterier

3. juli 2024

Først opslået (Faktiske)

11. juli 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • BC&SSH-001

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

IPD sharing may be considered upon personal application

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner